INHIBITION OF THE 5-HT-INDUCED CARDIOGENIC HYPERTENSIVE CHEMOREFLEX BY THE SELECTIVE 5-HT3 RECEPTOR ANTAGONIST ICS 205-930

被引：0
作者：
BERTHOLD, H
SCHOLTYSIK, G
ENGEL, G
机构：
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 1989年 / 339卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：259 / 262
页数：4
相关论文
共 50 条
[21]   ANTIEMETIC ACTION OF 5-HT-3 RECEPTOR ANTAGONISTS - REVIEW OF PRECLINICAL AND CLINICAL-RESULTS WITH ICS 205-930 [J].
GAMSE, R .
CANCER TREATMENT REVIEWS, 1990, 17 (2-3) :301-305
[22]   Evidence for 5-HT3 receptor involvement in the 5-HT-induced contraction in the mouse isolated ileum [J].
Tuladhar, BR ;
Womack, MD ;
Naylor, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 :U36-U36
[23]   ENHANCEMENT OF MEMORY RETRIEVAL AND ATTENUATION OF SCOPOLAMINE-INDUCED AMNESIA FOLLOWING ADMINISTRATION OF 5-HT3 ANTAGONIST ICS-205-930 [J].
CHUGH, Y ;
SAHA, N ;
SANKARANARAYANAN, A ;
DATTA, H .
PHARMACOLOGY & TOXICOLOGY, 1991, 69 (02) :105-106
[24]   THE 5-HT INDUCED BIPHASIC VASODILATATION IN THE HUMAN FOREARM IS DOSE-DEPENDENTLY ANTAGONIZED BY ICS 205-930 [J].
BLAUW, GJ ;
VANBRUMMELEN, P ;
VANZWIETEN, PA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) :P663-P664
[25]   EFFECTS OF THE 5-HT3 RECEPTOR ANTAGONIST, ICS 205-930, ON ESOPHAGEAL MOTOR-ACTIVITY AND ON LOWER ESOPHAGEAL SPHINCTER PRESSURE - A DOUBLE-BLIND CROSS-OVER STUDY [J].
STACHER, G ;
STEINER, G ;
GAUPMANN, G ;
STACHERJANOTTA, G ;
SCHNEIDER, C ;
STEINRINGER, H .
HEPATO-GASTROENTEROLOGY, 1990, 37 :118-121
[26]   THE ROLE OF 5-HT3 RECEPTOR-MEDIATED MECHANISMS ON 5-HT-INDUCED APNEA IN ANESTHETIZED RATS [J].
GODA, Y ;
YOSHIOKA, M ;
TOGASHI, H ;
ABE, M ;
SAITO, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) :705-706
[27]   THE EFFECTS OF ICS 205-930, A 5-HT ANTAGONIST, ON ARRHYTHMIAS AND CATECHOLAMINE RELEASE DURING CANINE MYOCARDIAL-ISCHEMIA AND REPERFUSION [J].
COKER, SJ ;
DEAN, HG ;
KANE, KA ;
PARRATT, JR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 127 (03) :211-218
[28]   A COMPARATIVE-STUDY OF THE USE OF NAVOBAN (ICS 205-930), A 5-HT3 ANTAGONIST, VERSUS A STANDARD ANTIEMETIC REGIMEN OF DEXAMETHASONE AND METOCLOPRAMIDE IN THE TREATMENT OF CISPLATIN-CONTAINING CHEMOTHERAPY [J].
MADEJ, G ;
KRZAKOWSKI, M ;
PAWINSKI, A ;
LASOTA, W ;
ROGOWSKI, W ;
SKONECZNA, I .
DRUG INVESTIGATION, 1993, 6 (03) :162-169
[29]   The inhibition of cholera toxin-induced 5-HT release by the 5-HT3 receptor antagonist, granisetron, in the rat [J].
Turvill, JL ;
Connor, P ;
Farthing, MJG .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (05) :1031-1036
[30]   CHARACTERIZATION OF 5-HT3 RECOGNITION SITES IN MEMBRANES OF NG 108-15 NEUROBLASTOMA-GLIOMA CELLS WITH [H-3] ICS 205-930 [J].
NEIJT, HC ;
KARPF, A ;
SCHOEFFTER, P ;
ENGEL, G ;
HOYER, D .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1988, 337 (05) :493-499
12345